Abstract:Rong Liu, 1, &ast Min Zhu, 2, &ast Jiaojiao Chen, 3 Junwei Gai, 2 Jing Huang, 2 Yingqun Zhou, 1 Yakun Wan, 2 Chuantao Tu 4 1 Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, People's Republic of China; 2 Shanghai Novamab Biopharmaceuticals Co., Ltd, Shanghai, 201318, People's Republic of China; 3 Department of Gastroenterology, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, 200434, People's Republic of China; 4 Department of Gastroenterology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People's Republic of China &astThese authors contributed equally to this work Correspondence: Chuantao Tu; Yakun Wan, Email ; Background: No agents are currently available for the treatment or reversal of liver fibrosis. Novel antifibrotic therapies for chronic liver diseases are thus urgently needed. Connective tissue growth factor (CTGF) has been shown to contributes profoundly to liver fibrogenesis, which makes CTGF as a promising target for developing antifibrotic agents. Methods: In this study, we identified a novel nanobody (Nb) against human CTGF (anti-CTGF Nb) by phage display using an immunized camel, which showed high affinity and specificity in vitro. LX-2 cells, the immortalized human hepatic stellate cells, were induced by transforming growth factor beta1 (TGFβ 1) as an in vitro model of liver fibrosis to verify the antifibrotic activity of the anti-CTGF Nb. Results: Our data demonstrated that anti-CTGF Nb effectively alleviated TGFβ 1-induced LX-2 cell proliferation, activation, and migration, and promoted the apoptosis of activated LX-2 cells in response to TGFβ 1. Moreover, the anti-CTGF Nb remarkably reduced the levels of TGFβ 1, Smad2, and Smad3 expression in LX-2 stellate cells stimulated by TGFβ 1. Conclusion: Taken together, we successfully identified a novel Nb against human CTGF, which exhibited antifibrotic effects in vitro by regulating the biological functions of human stellate cells LX-2. Graphical Keywords: nanobody, connective tissue growth factor, liver fibrosis, hepatic stellate cells Graphical Chronic liver injury of various etiologies can lead to liver fibrosis characterized by excessive accumulation of extracellular matrix (ECM) in the liver. 1–3 If remain unresolved, liver fibrosis may progress to cirrhosis, liver failure, and even hepatocellular carcinoma (HCC). 1 Chronic fibrotic liver disease and cirrhosis represent a major global health challenge. However, there are currently no approved therapeutic agents to treat or reverse liver fibrosis. 1,2 Therefore, a deep understanding of molecular mechanisms underlying hepatic fibrogenesis is needed to identify potential targets for antifibrotic therapies. Hepatic stellate cells (HSCs) have been identified as the primary precursor cells of myofibroblasts (MFBs), which orchestrate the deposition of ECM in normal and fibrotic liver. 1–3 Upon liver injury, hepatocytes and nonparenchymal cells, such as Kupffer cells, endothelial cells, and neutrophil granulocytes, release cytokines and chemokines, ultimately activate HSCs to release their vitamin A and retinoid stores, and undergo dramatic phenotypic alterations, and transdifferentiate into MFBs. 1,3–5 Furthermore, the activated MFBs exhibit a variety of cellular processes such as proliferation, migration, contractility, and apoptosis resistance, accompanied by secretion of cytokines, chemokines, and ECM components. 4 Thus, targeting the activation of MFBs are emerging as a high potential a strategy for treating liver fibrosis. 1,6 Transforming growth factor beta (TGFβ) signaling is considered as a master profibrogenic pathway responsible for ECM production and plays a key role in the pathogenesis of liver fibrosis. 7–9 TGFβ1 is the principal isoform of TGFβ which mediates SMAD2/3 dependent pathway, commonly activating HSCs and stimulating the production of ECM synthesis. 7,8 Therefore, blocking TGFβ signaling represents an attractive antifibrotic therapy. 5,7 However, TGFβ is a multifunctional cytokine and has important roles in liver physiology, and its inhibition results in undesirable side effects, 5,7,10 which is a major challenge for translation into use of the clinic. Therefore, an improved understanding of the downstream regulatory mechanisms of TGF-β may help develop therapeutic strategies against liver fibrosis. 7 Connective tissue growth factor (CT -Abstract Truncated-

Identification of a Novel TGF-β-miR-122-fibronectin 1/serum Response Factor Signaling Cascade and Its Implication in Hepatic Fibrogenesis

Upregulation of Mirna-1228-3p Alleviates TGF-β-induced Fibrosis in Renal Tubular Epithelial Cells.

Mir-301A-3p Promotes Hepatic Stellate Cells Activation and Liver Fibrogenesis Via Regulating PTEN/PDGFR-β.

MicroRNA-146b Regulates Hepatic Stellate Cell Activation Via Targeting of KLF4.

MiR-542-3p controls hepatic stellate cell activation and fibrosis via targeting BMP-7.

TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis

The role of the miR-31/FIH1 pathway in TGF-β-induced liver fibrosis.

miR-140-5p attenuates hepatic fibrosis by directly targeting TGFβR1

MicroRNAs in Transforming Growth Factor-Beta Signaling Pathway Associated With Fibrosis Involving Different Systems of the Human Body

The miR-23b/27b/24-1 Cluster Inhibits Hepatic Fibrosis by Inactivating Hepatic Stellate Cells

Integration of high‑throughput data of microRNA and mRNA expression profiles reveals novel insights into the mechanism of liver fibrosis.

Targeting Follistatin like 1 ameliorates liver fibrosis induced by carbon tetrachloride through TGF-β1-miR29a in mice

MicroRNA-101 suppresses liver fibrosis by targeting the TGFβ signalling pathway.

Identification and Characterization of a Novel Nanobody Against Human CTGF to Reveal Its Antifibrotic Effect in an in vitro Model of Liver Fibrosis

Anti-Liver Fibrosis Role of miRNA-96-5p via Targeting FN1 and Inhibiting ECM-Receptor Interaction Pathway

miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression

Mir-345–5P Curbs Hepatic Stellate Cell Activation and Liver Fibrosis Progression by Suppressing Hypoxia-Inducible Factor-1Alpha Expression

TGF-β induces liver fibrosis via miRNA-181a-mediated down regulation of augmenter of liver regeneration in hepatic stellate cells

miR-133a mediates TGF-β-dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis

Serum Exosome-Derived microRNA-193a-5p and miR-381-3p Regulate Adenosine 5'-Monophosphate-Activated Protein Kinase/Transforming Growth Factor Beta/Smad2/3 Signaling Pathway and Promote Fibrogenesis

MicroRNA-34a: A Novel Therapeutic Target in Fibrosis